



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stephen J. Lippard, et al.

Serial No: 10/755,855

Filed: January 12, 2004

For: *Coordination Complexes Having
Tethered Therapeutic Agents and/or
Targeting Moieties, and Methods of
Making and Using the Same*

Examiner: To be assigned

Art Unit: 1614

Attorney Docket No. MTV-061.01

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on the date set forth below.

January 13, 2005
Date of Signature and Mail Deposit

By:


John Barretto

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97 (b)(3)

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants and/or their attorney to be in compliance with the requirements of 37 CFR § 1.56. A copy of documents CK-CZ, DA-DZ, and EA-EE, Foreign Patent Documents and Other Documents, are also being submitted herewith. A copy of documents AA-CJ, U.S. Patent Documents, are not provided.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.


Under 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fees as required under 37 C.F.R. § 1.17(p) to our **Deposit Account No. 06-1448, Reference: MTV-061.01.**

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1753.

Respectfully Submitted,

Date: January 13, 2005

Customer No. 25181
Patent Group
Foley, Hoag LLP
155 Seaport Boulevard
Boston, MA 02210



Michael J. DiVerdi, Ph.D.
Reg. No. 51,620
Agent for Applicants

Form PTO-1449

**SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)


Packet Number (Optional)
MTV-051.01

Applicant
Lippard, Stephen J., et al.

Filing Date
January 12, 2004

Application Number
10 755,855

Group Art Unit
1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,547,982	08-20-96	Abrams, et al.	514	492
	AB	4,271,085	06-02-81	Amundsen, et al.	556	1376
	AC	4,457,926	07-03-84	Amundsen, et al.	514	184
	AD	4,462,998	07-31-84	Amundsen, et al.	514	184
	AE	4,505,928	03-19-85	Amundsen, et al.	514	492
	AF	5,519,155	05-21-96	Barnard, et al.	556	137
	AG	5,225,207	07-06-93	Barreau, et al.	424	649
	AH	2004/0006051	01-08-04	Berube	514	169
	AI	6,825,330	11-30-04	Braman, et al.	536	23.1
	AJ	5,484,612	01-16-96	Brown	424	649
	AK	5,194,644	03-16-93	Brunner, et al.		
	AL	5,238,955	08-24-93	Brunner, et al.		
	AM	6,313,333	11-06-01	Da Re, et al.	556	137
	AN	4,937,262	06-26-90	Davidson	514	492
	AO	4,659,849	04-21-87	Drobnik, et al.	556	137
	AP	5,028,726	07-02-91	Farrell	556	137
	AQ	5,409,915	04-25-95	Farrell, et al.	514	187
	AR	5,624,919	04-29-97	Farrell	514	184
	AS	5,770,591	06-23-98	Farrell	514	187
	AT	6,022,892	02-08-00	Farrell, et al.	514	492
	AU	6,060,616	05-09-00	Farrell, et al.	556	137
	AV	6,113,934	09-05-00	Farrell, et al.	424	405
	AW	4,760,155	07-26-88	Heffernan, et al.	556	136
	AX	4,760,156	07-26-88	Heffernan, et al.	556	136
	AY	4,952,676	08-28-90	Heffernan, et al.	530	391.5
	AZ	4,956,454	09-11-90	Heffernan, et al.	424	179.1
	BA	4,577,018	03-18-86	Hlavka, et al.	544	225

Form PTO-1449			Docket Number (Optional) MTV-061.01		Application Number 10 755,855	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>			Applicant Lippard, Stephen J., et al.			
			Filing Date January 12, 2004		Group Art Unit 1614	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BB	4,234,500	11-18-80	Hoeschele, et al.	556	17
	BC	4,291,027	09-22-81	Hoeschel, et al.	514	76
	BD	5,380,897	01-10-95	Hoeschele, et al.	556	137
	BE	5,714,327	02-03-98	Houthoff, et al.	435	6
	BF	5,985,566	11-16-99	Houthoff, et al.	435	6
	BG	6,133,038	10-17-00	Houthoff, et al.	436	84
	BH	6,248,531	06-19-01	Houthoff, et al.	435	6
	BI	5,256,653	10-26-93	Keppler, et al.	514	79
	BJ	4,416,878	11-22-83	Klosa	514	186
	BK	4,870,062	09-26-89	Kurono, et al.	514	63
	BL	4,843,161	06-27-89	Lippard, et al.	546	10
	BM	4,284,579	08-18-81	Meischen, et al.	556	19
	BN	4,428,943	01-31-84	Meischen, et al.	514	119
	BO	5,902,826	05-11-99	Mogi, et al.	514	492
	BP	4,912,100	03-27-90	Ohno, et al.	514	184
	BQ	4,980,347	12-25-90	Ohno, et al.	514	186
	BR	4,732,893	03-22-88	Pasini, et al.	514	185
	BS	5,198,564	03-30-93	Quianhuan	556	137
	BT	6,605,734	08-12-03	Roy, et al.	556	9
	BU	4,793,986	12-27-88	Serino, et al.	424	1.53
	BV	6,130,245	10-10-00	Shaw	514	492
	BW	4,921,963	05-01-90	Skov, et al.	548	101
	BX	5,026,694	06-25-91	Skov, et al.	514	184
	BY	6,333,422	12-25-01	Sohn, et al.	556	17
	BZ	5,104,895	04-14-92	Spinelli, et al.	514	492

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) MTV-051.01	Application Number 10 755,855
	Applicant Lippard, Stephen J., et al.	
	Filing Date January 12, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA 6,692,734	02-17-04	Stewart, et al.	424	78.27	
	CB 4,590,001	05-20-86	Stjernholm	530	394	
	CC RE33,071	09-26-89	Stjernholm	530	394	
	CD 5,633,243	05-27-97	Sugimura, et al.	514	184	
	CE 4,560,781	12-24-85	Totani, et al.	556	137	
	CF 5,744,497	04-28-98	Valsecchi, et al.e	514	492	
	CG 6,011,166	01-04-00	Valsecchi, et al.	556	137	
	CH 4,992,553	02-12-91	Von Angerer, et al.	546	12	
	CI 5,561,042	10-01-96	Weis, et al.	435	6	
	CJ 5,498,780	03-12-96	Yokoi, et al.	514	492	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	CK WO 03/017993	03-06-03	PCT				
	CL EP 1 262 778	04-12-02	EPO				
	CM WO 00/27847	05-18-00	PCT				
	CN WO 96/35696	11-14-96	PCT				
	CO 0 169 645	01-29-06	EPO				

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

	CP	ARAP, Wadih, et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science, Vol. 279, 16 January 1998, pp. 377-380.
	CQ	BROWN, Steven J., et al., "1xr1, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin," Science, Vol. 261, 30 July 1993, pp. 603 - 605.
	CR	CHEN, Lie, et al., "Reduction of the anti-cancer drug analogue <i>cis, trans, cis</i> -[PtCl ₂ (OCOCH ₃) ₂ (NH ₃) ₂] by L-cysteine and L-methionine and its crystal structure," <i>J. Chem. Soc., Dalton Trans.</i> , 1999, pp. 1209-1212.
	CS	COHEN, Seth M., et al., "Cisplatin: From DNA Damage to Cancer Chemotherapy," Progress in Nucleic Acid Research and Molecular Biology, Vol. 67, 2001, pp. 93-130.
	CT	DHARA, S.C., "A Rapid Method for the Synthesis of <i>cis</i> -[Pt(NH ₃) ₂ Cl ₂], Indian Journal of Chemistry, Vol. 8, No. 2, February 1970, pp. 193-194.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) MTV-051.01	Application Number 10 755,855
	Applicant Lippard, Stephen J., et al.	
	Filing Date January 12, 2004	Group Art Unit 1614

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

CU	ELLERBY, H. Michael, et al., "Anti-cancer activity of targeted pro-apoptotic peptides," <i>Nature Medicine</i> , Vol. 5, No. 9, September, 1999, pp. 1032-1038.
CV	FOLKMAN, Judah, "What Is the Evidence That Tumors Are Angiogenesis Dependent?," <i>Journal of the National Cancer Institute</i> , Vol. 82, No. 1, January 3, 1990, pp. 4-6.
CW	FOLKMAN, Judah, <i>Alternative Strategies for Biologic Therapy</i> , Chapter 30, Antiangiogenesis, pp. 743-753.
CX	FOLKMAN, Judah, et al., "Minireview, Angiogenesis," <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, Issue of June 5, 1992, pp. 1031-1034.
CY	GIANDOMENICO, Christen M., et al., "Carboxylation of Kinetically Inert Platinum (IV) Hydroxy Complexes. An Entrée into Orally Active Platinum(IV) Antitumor Agents," <i>Inorganic Chemistry</i> , Vol. 34, No. 5, 1995, pp. 1015-1021.
CZ	HAMBLEY, T.W., et al., "Modifying the Properties of Platinum (IV) Complexes in Order to Increase Biological Effectiveness," <i>Journal of Inorganic Biochemistry</i> , 77 (1999), pp. 3-12.
DA	HAMMES, Hans-Peter, et al., "Subcutaneous Injection of a Cyclic Peptide Antagonist of Vitronectin Receptor-Type Integrins Inhibits Retinal Neovascularization," <i>Nature Medicine</i> , Vol. 2, No. 5, May 1996, pp. 529-533.
DB	HART, Stephen L, et al., "Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 17, Issue of April 29, 1994, pp. 12468-12474.
DC	HEALY, Judith M., et al., "Peptide Ligands for Integrin $\alpha_5\beta_1$ Selected from Random Phage Display Libraries," <i>Biochemistry</i> , Vol. 34, No. 12, 1995, pp. 3948-3955.
DD	HOUSTON, Parul, et al., "Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging," <i>Federation of European Biochemical Societies</i> , 2001, pp. 73-77.
DE	HUANG, Juch-Chin, et al., "HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, October 1994, pp. 10394-10398.
DF	JAMIESON, Elizabeth R., et al., "Structure, Recognition, and Processing of Cisplatin--DNA Adducts," <i>Chemical Reviews</i> , 1999, pp. 2467-2498.
DG	KARTALOU, Maria, et al., "Recognition of cisplatin adducts by cellular proteins," <i>Mutation Research</i> 478 (2001), pp. 1-21.
DH	KOIVUNEN, Erkki, et al., "Isolation of a Highly Specific Ligand for the $\alpha_5\beta_1$ Integrin from a Phage Display Library," <i>The Journal of Cell Biology</i> , Vol. 124, No. 5, February 1994, pp. 373-380.
DI	KOIVUNEN, Erkki, et al., "Selection of Peptides Binding to the $\alpha_5\beta_1$ Integrin from Phage Display Library," <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 27, Issue of September 25, 1993, pp. 20205-20210.
DJ	KOIVUNEN, Erkki, et al., "Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins," <i>Bio/Technology</i> , Vol. 13, March 1995, pp. 265-270.
DK	LEE, Keng-Boon, et al., "Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro," <i>PNAS</i> , Vol. 99, No. 7, April 2, 2002, pp. 4239-4244.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) MTV-061.01	Application Number 10/755,855
	Applicant Lippard, Stephen J., et al.	
	Filing Date January 12, 2004	Group Art Unit 1614

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

DL	LEE, Young-A, et al., "Synthesis and Oral Antitumor Activity of Tetrakis (carboxylato) platinum (IV) Complexes," <i>J. Med. Chem.</i> , Vol. 43, No. 7, 2000, pp. 1409-1412.
DM	LEMMA, Kelemu, et al., "Kinetics and Mechanism for Reduction of the Anticancer Prodrug trans,trans,trans-[PtCl ₂ (OH) ₂ (c-C ₆ H ₁₁ NH ₂)(NH ₃)] (JM335) by Thiols," <i>Inorganic Chemistry</i> , Vol. 39, No. 8, 2000, pp. 1728-1734.
DN	LEMMA, Kelemu, et al., "Kinetics and Mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione," <i>Journal of Biological Inorganic Chemistry</i> , Vol. 5, No. 3, June, 2000, pp. 300-306.
DO	LEMMA, Kelemu, et al., "Kinetics and mechanism for reduction of halo-and haloam(m)ine platinum(IV) complexes by L-ascorbate," <i>Inorganica Chimica Acta</i> , 331,2002, pp. 98-108.
DP	MACLUSKY, NEIL J., et al., "Actions of an Estradiol-17-Fatty Acid Ester in Estrogen Target Tissues of the Rat: Comparison with Other C-17 Metabolites and a Pharmacological C-17 Ester," <i>Endocrinology</i> , Vol. 124, No. 1, 1989, pp. 318-324.
DQ	ORME, Mark W., et al., "Synthesis of β -Estradiol-3-Benzoyl-17-(Succinyl-12A-Tetracycline): A Potential Bone-Seeking Estrogen," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 11, 1994, pp. 1375-1380.
DR	PASQUALINI, Renata, et al., "Organ targeting in vivo using phage display peptide libraries," <i>Nature</i> , Vol. 380, 28 March 1996, pp. 364-366.
DS	QING, He, et al., "Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin," <i>PNAS</i> , Vol. 97, No. 11, May 23, 2000, pp. 5768-5772.
DT	RAJOTTE, Daniel, et al., "Molecular Heterogeneity of the Vascular Endothelium Revealed by In Vivo Phage Display," <i>J. Clin. Invest.</i> , Vol. 102, No. 2, July 1998, pp. 430-437.
DU	REEDIJK, Jan, "The mechanism of action of platinum anti-tumor drugs," <i>Pure & Appl. Chem.</i> , Vol. 59, No. 2, 1987, pp. 181-192.
DV	ROSENBERG, Barnett, et al., "Inhibition of Cell Division in <i>Escherichia coli</i> by Electrolysis Products from a Platinum Electrode," <i>Nature</i> , Vol. 205, February 13, 1965, pp. 698-698.
DW	RUOSLAHTI, Erkki, "Specialization of Tumour Vasculature," <i>Nature Reviews</i> , Vol. 2, February, 2002, pp. 83-90.
DX	SHI, Tiesheng, et al., "Reduction of trans-dichloro- and trans-dibromo-tetracyano-platinate (IV) by L-methionine," <i>J Chem.Soc., Dalton Trans.</i> , 1997, pp. 2073-2077.
DY	SHI, Tiesheng, et al., "Kinetics and Methanism for Reduction of trans-Dichlorotetracyanoplatinate(IV) by "Thioglycolic Acid, L-Cysteine, DL-Penicillamine, and Glutathione in Aqueous Solution," <i>Inorganic Chemistry</i> , Vol. 35, No. 12, 1996, pp. 3498-3503.
DZ	TAKAHARA, Patricia M., et al., "Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA," <i>J. Am. Chem. Soc.</i> , Vol. 118, No. 49, 1996, pp. 12309-12321.
EA	TREIBER, Daniel K., et al., "Cisplatin--DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor), <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, June 1994, pp. 5672-5676.
EB	TREPEL, M., et al., "Exploring vascular heterogeneity for gene therapy targeting," <i>Gene Therapy</i> , 2000.

Form PTO-1449	SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) MTV-061.01	Application Number 10 755,855
Applicant Lippard, Stephen J., et al.			
Filing Date January 12, 2004		Group Art Unit 1614	

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

EC	TRIMMER, Elizabeth E., et al., "Cisplatin," Essays in Biochemistry, Vol. 34, 1999, pp. 191-211.
ED	WONG, Ernest, et al., "Current Status of Platinum-Based Antitumor Drugs," <i>Chem. Rev.</i> Vol. 99, No. 9, 1999, pp. 2451-2466.
EE	ZIEGLER, Christopher J., et al., "High-throughput synthesis and screening of platinum drug candidates," <i>J. Biol. Inorg. Chem.</i> , 2000, pp. 774-783.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE